Last week I explained why my firm is investing in pharmaceuticals stocks, despite the sector being a favorite punching bag of politicians. I noted that we have recently added to our existing positions in Amgen, Allergan, and Gilead Sciences, and I promised that I would unveil two new positions this week. Drumroll, please:
Mylan has two businesses: It is one of the top three global generic drug manufacturers (the source of the bulk of its revenue), and it is the maker of the EpiPen. Its stock peaked at $76.06 in April of 2015 and but halved by the end of 2016 before rallying this year.
The stock decline accelerated in 2016 after Mylan made a horrible public relations misstep when it doubled the price of its EpiPen from $300 to $600. The EpiPen is a handheld device that injects adrenalin to prevent an allergic reaction from causing asphyxiation. Mylan has raised prices on the EpiPen 10 to 15 percent twice a year over a five-year period, increasing the cost at least three to four times. The EpiPen patent expired long ago, but there has been no generic competitor on the market.
Qualivian Investment Partners Up 30% YTD; Long ORLY Thesis
Qualivian Investment Partners commentary for the second quarter ended July 30, 2020. Q2 2020 hedge fund letters, conferences and more “Short-term investors will accept a 20% gain because they didn’t spend the time to develop the conviction and foresight to see the next 500%.” - Ian Cassell Executive Summary Readers of investment letters fall into Read More
The EpiPen fiasco has created an opportunity. Mylan’s generics make up a decent, stable business that just spits out a lot of cash flow (we like the pricing power of branded pharmaceuticals companies more). Mylan will be bringing a generic EpiPen to the market at a 40 percent lower price point this year. Despite the negative PR and commotion, EpiPen will contribute about 50 cents to Mylan’s earnings in 2017, which we expect to be around $5.50 a share and then grow to $6 to $7 by 2019. At six times earnings Mylan is simply too cheap to ignore.
McKesson is one of the top three drug distributors in the U.S. McKesson, Cardinal Health, and AmerisourceBergen are all about the same size and together control over 90 percent of the pharmaceuticals distribution market. The fact that all three companies are a similar size is very important to the long-term health of the industry — and thus to McKesson’s long-term earnings power. When you have a sector dominated by a few (let’s say three or four) players of different sizes, a smaller company may feel that it is at a competitive disadvantage and start a price war (forgoing short-term profitability) to gain additional market share — and thus undermine the industry’s stable pricing structure. The wireless sector in the U.S. is a great example of that: There are four players, but AT&T and Verizon are double the size of T-Mobile and Sprint. After Sprint’s overture to buy T-Mobile was blocked by regulators, T-Mobile initiated a price war that, combined with its creative marketing, allowed it to steal customers from Verizon and AT&T — a win for consumers, but it flatlined AT&T and Verizon earnings.
Back to drug distributors. Since all the players are approximately the same size, we are unlikely to see a price war, though there may be healthy short-term flare-ups of competition.
We have owned Cardinal Health and McKesson (more than once) in the past and know this business well. Think of these companies as railroads for prescriptions and generic drugs in the U.S. Pfizer, for instance, doesn’t want to deal with hundreds of pharmacies, nor does it have the scale to do so. Pfizer pays McKesson a small fee to distribute its drugs to pharmacies and hospitals.
The drug distribution industry was affected by the deceleration of pharmaceuticals price inflation in the second half of 2016 — it was political season, and pharma companies did not want to give politicians extra ammunition. (Mylan and a few others had done plenty of that already.)
You may hate this as an American consumer, but pharmaceuticals price inflation is a fact of life. We are less likely to see EpiPen-like increases going forward, but on its latest earnings call McKesson projected mid- to high-single-digit price inflation for branded drugs. The CEO of Allergan, at a conference in early January, basically said that the company will be raising prices once (not twice!) a year by mid-single digits.
Here is how we view McKesson: It’s an oligopolylike business with a high return on capital, a terrific balance sheet (it could pay off all of its debt in one year), and great cash flows. It is organically growing revenue 5 to 6 percent a year and returning cash to us through share buybacks and dividends.
Let’s focus on cash flows a bit further. McKesson generates about $3 billion a year of free cash flows — cash earnings that are left after a company has paid for all of its ongoing expenses and invested in fixed assets (equipment, buildings, etc.) required to maintain its current earnings power. The beauty of McKesson’s business is that it doesn’t consume a lot of capital, and so incremental growth doesn’t cost much. Thus the company can grow revenue and net income 5 to 6 percent a year without much incremental investment.
McKesson’s management has several options for what it can do with $3 billion of free cash flows: It can increase its dividend (McKesson pays a small dividend of 0.8 percent that it has promised to raise over time); it can buy back its own stock if it is cheap (McKesson has done some of that); it can pay down debt (it has little debt, so paying that down is not a high priority); or, finally, it can make acquisitions that will add to McKesson’s growth. (McKesson has made acquisitions from time to time.)
If McKesson management spends its free cash flow wisely on dividends, buying back stock, or making acquisitions, then 5 to 6 percent organic growth will accelerate to the mid-teens.
McKesson is a growing business of very high quality, and we paid only about ten times earnings, or less than half of what the stock market is paying for the privilege of owning Coca-Cola.
Tired of generic investment advice.
Read: What. How. Why.
Are you enjoying my articles? If so, please forward them to your friends, enemies, neighbors, and random strangers. Suggest that they sign up for my future articles (or you’ll have to keep forwarding them).
I want to address an issue that has bothered me for a while now. When I write about stocks my musings are not recommendations but just thoughts on stocks at this point in time. I am usually very clear whether we own a company I am writing about. (I don’t usually write about small companies as I don’t want to create even an appearance of trying to influence a stock price.)
My articles are static thoughts at a fixed point in time. However, as you well know, investing is not a static endeavor. New information comes in all the time. Sometimes it causes us to adjust the assumptions in our models and may cause us to change our views on companies. As Keynes may or may not have said, “When the facts change, I change my mind.” We may buy more of a company, sell it, or do nothing. Our thinking is rarely driven by the stock price change alone, unless the price has reached our sell price.
If you buy a stock based solely on my write-up, without doing your own research, then you are committing yourself to a static analysis. I may have already changed my mind. My writing is about teaching you how to fish and is never about providing the fish. If you like the sound of a company I write about, do your own research to firm up your own conclusions. Stress test my assumptions and form your own assumptions.
By the way, this is exactly what I do all the time. I talk to hundreds of like-minded investors a year. We share ideas. If I like an idea, we start doing our own research. We read the company’s filings, talk to management, build our models… the usual stuff. And then we arrive at our conclusion … and may even buy the stock.
Value investors are the buyers of hate. We often ride the wave of negative momentum. We try to buy $1 for less, let’s say 50 cents. The reason the $1 is selling for less is because that road in the short run may prove to be very rocky and unpleasant. Trust me on this; my rapidly balding head is a testament to it.
My long-term readers will remember my Electronic Arts adventure. We started buying at around $16, and then it seemed that the stock declined every day for eight months. It seemed that every bit of news that came out about the gaming industry and EA was negative. Until it was not. (Here is my EA presentation, and here is the article). If you had bought EA blindly based on my article, the next eight months would have been very painful, because to you there was no difference between the stock’s quoted price and its intrinsic value (what the company was worth). I think the stock bottomed 30% or 40% lower before it started its ascent.
Please, do your own research.
Music note from MyFavoriteClassical.com
Franz Liszt’s Piano Concerto No. 2. If I had to use one phrase to describe this wonderful masterpiece, I’d say it is a “concert of contrast.” Everything in this concerto has an opposite. If part of it sounds soft and lyrical, just wait and you’ll be treated to a forceful, military march-like section. If it’s quiet, don’t worry, it will get very loud very soon. If it sounds gentle and bright, don’t get used to it; deep darkness lies just a few notes away. There is love and of course devilish hate here, too.
This roller coaster of contrasts has its purpose: It is there to reach into your soul, turn it upside down, and squeeze every possible ounce of emotion out of you. The roller coaster of contrasts is life! Life without contrasts would be bland and boring. Contrasts are what make us appreciate what we have (and what we might have, and what we have lost). We would not appreciate the beauty of sunrise without the darkness of night. Pain is there for us to value the scarcity of joy. And love is there when we transcend blindness of indifference. It is impossible (speaking from personal experience) to listen to this concerto and not be deeply impacted by it.
P.S. I didn’t actually mean to get carried away, but I’ve been listening to this concerto all day long, and it stirred up so much emotion in me that you got the above.
Khatia Buniatishvili – beautiful performance, though I am not sure I can be totally objective here
The Pharmaceuticals Stocks We’re Buying Now By Vitaliy Katsenelson, CFA
Originally written for Institutional Investor Magazine
>Vitaliy N. Katsenelson, CFA, is Chief Investment Officer at Investment Management Associates in Denver, Colo. He is the author of Active Value Investing (Wiley) and The Little Book of Sideways Markets (Wiley).